COVID Frankenstein Variant: Hospital Infections Rising
- Summary: A new COVID-19 variant, nicknamed "Frankenstein" (officially BA.2.86), is gaining attention due to a high number of mutations.
- * Genetic Profile: BA.2.86 is a descendant of Omicron, but possesses over 30 mutations in its spike protein compared to previous variants.
- * Immune Evasion: The large number of mutations raises concerns about the variant's ability to evade immunity from prior infection and vaccination.
COVID-19 “frankenstein” Variant: What You Need to Know
Summary: A new COVID-19 variant, nicknamed ”Frankenstein” (officially BA.2.86), is gaining attention due to a high number of mutations. While early data suggests it doesn’t cause more severe illness,its increased transmissibility and potential to evade existing immunity are raising concerns. Here’s a breakdown of what we know, why it matters, and what to expect next.
1. What is the ”Frankenstein” Variant (BA.2.86)?
* Genetic Profile: BA.2.86 is a descendant of Omicron, but possesses over 30 mutations in its spike protein compared to previous variants. this meaningful jump in mutations is what earned it the “Frankenstein” moniker.
* First Detection: The variant was first detected in Denmark in late July 2023, and has since been identified in several other countries including the US, UK, Israel, and Switzerland.
* Severity: Currently, there’s no evidence to suggest BA.2.86 causes more severe illness than other circulating variants. hospitalization rates linked to this variant are being closely monitored. However, it’s still early days.
* symptoms: Reports indicate symptoms are similar to other Omicron variants – sore throat, runny nose, congestion, cough, fatigue, and sometiems fever. Some reports suggest a return of some earlier symptoms like loss of smell/taste, but this is not yet confirmed as specific to BA.2.86.
2. Why Does it Matter?
* Immune Evasion: The large number of mutations raises concerns about the variant’s ability to evade immunity from prior infection and vaccination. Early lab studies suggest a reduction in antibody neutralization, but the extent of this evasion is still being investigated.
* Increased Transmissibility: While not definitively proven, the genetic changes suggest BA.2.86 could be more transmissible than existing variants. This is a key area of concern.
* Potential for New Wave: If BA.2.86 proves to be considerably more transmissible and able to evade immunity, it could lead to a new wave of infections, particularly as we enter the fall and winter months.
* Global Spread: The variant’s detection in multiple countries indicates it’s already spreading internationally.
3. What’s Next?
* Continued Monitoring: Public health agencies (WHO, CDC, ECDC) are closely monitoring the spread of BA.2.86 through genomic surveillance.
* Vaccine Updates: Vaccine manufacturers (Pfizer, Moderna, Novavax) are evaluating the variant and are prepared to update vaccines if necessary. The updated vaccines expected in Fall 2023 are designed to target XBB.1.5, and initial assessments suggest they will still offer some protection against BA.2.86.
* Boosters: Health officials are recommending that individuals stay up-to-date with their COVID-19 vaccinations, including boosters, to maintain a level of protection. The question of whether a new booster specifically targeting BA.2.86 will be needed is under evaluation.
* Public Health Measures: While widespread lockdowns are unlikely, public health officials may recommend increased precautions, such as masking in crowded indoor spaces, improved ventilation, and staying home when sick.
* Research: Ongoing research is crucial to understand the variant’s transmissibility, severity, and response to existing treatments.
4. Data Snapshot (as of September 1,2023)
| Country | Cases Reported (BA.2.86) | % of Cases (Estimate) |
|---|---|---|
| united States | 6+ | <1% |
| United kingdom | 8+ | <1% |
| Denmark | 40+ | ~2% |
| Israel |